ThromboView moves to phase II testing

Australian pharmaceutical developer Agenix will move its ThromboView radiopharmaceutical to phase II clinical testing, following successful completion of a phase Ia clinical trial and an interim review of an ongoing phase Ib trial in patients with deep vein thrombosis (DVT).

The Brisbane-based firm said that the phase II clinical trials will be performed under an investigational new drug (IND) application to be filed with the Food and Drug Administration in the second half of 2004, as well as a clinical trial application in Canada.

By AuntMinnie.com staff writers
May 18, 2004

Related Reading

Agenix readies IND application for ThromboView, February 12, 2004

Copyright © 2004 AuntMinnie.com

Page 1 of 597
Next Page